medigraphic.com
ISSN 0016-3813 (Print)

2014, Number 6

<< Back Next >>

Gac Med Mex 2014; 150 (6)

18F-FDG PET/CT. Its correlation with carcinoembryonic antigen in patients with colorectal carcinoma

Granados RO, Estrada G, Altamirano J

Language: Spanish
References: 19
Page: 509-517
PDF size: 422.48 Kb.


ABSTRACT

Background: 18F-FDG PET has been shown to be highly accurate for recurrent and metastatic disease as well as in restaging. The carcinoembryonic antigen (CEA) can be used as a marker of prognosis and recurrence. Objective: To evaluate the association between the presence of lesions detected with 18F-FDG PET/CT and CEA values in patients with colorectal carcinoma. Material and methods: We reviewed the records of 2,051 patients who underwent PET/CT to identify all the patients with colorectal carcinoma and previous CEA. Results: We included a total of 101 patients, 51 women and 50 men, with an average age of 60.21 years. The clinical stage that prevailed was ECIIA, with moderately differentiated adenocarcinoma histology (88.12%). There was agreement between the elevation of CEA and lesions detected by PET/CT in 73.9%. From the patients with normal values of CEA, in 42% the PET/CT study was positive for tumoral recurrence or metastases. Conclusions: Our study revealed that 18F-FDG PET/CT can provided additional information in up to 42% of patients with normal ranges of carcinoembryonic antigen, detecting early recurrence or metastases.


REFERENCES

  1. Herrera GR. Carcinoma de colon y recto. Diagnóstico histológico y estadificación. Gamo. 2008;7 Suppl 4:22-30.

  2. Erazo VSA. Cáncer de colon. Gamo. 2008;7:1.

  3. Yee J. 2001 Plenary session: Friday imaging symposium. CT screening for colorectal cancer. Radiographics. 2002;22(6):1525-31.

  4. Tirado GL, Mohar BA. Epidemiología del cáncer de colon y recto. Gamo. 2008;7 Suppl 4:3-11.

  5. Morgan VG, Silva UA, Sat MD. Factores de riesgo para cáncer colorrectal. Gamo. 2008;7 Suppl 4:12-5.

  6. Calderillo RG, Ruiz MJ, Moreno VJ, Trejo DG, Padilla RA. Cáncer Colorrectal. En: Manual de Oncología. Procedimientos médico quirúrgicos. (4.ª ed.) Granados GM, Herrera GA, editores. México D.F.: McGraw-Hill; 2010. pp. 595-608.

  7. Ávila ME. Tratamiento quirúrgico en colon. Gamo. 2008;7 Suppl 4:31-3.

  8. Scott AM, Gunawardana DH, Kelley B, et al. PET Changes Managemente and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med. 2008;49(9):1451-7.

  9. Blodgett TM, Ryan A, Almusa O, Papachristou M, Paidisetty S. Cáncer colorrectal. En: Especialidades en imagen. PET/TC. Imagen oncológica con PET/TC diagnóstica. Blodgett TM, Ryan A, Almusa O, Papachristou M, Paidisetty S. Madrid: Ed. Marbán; 2012. pp. 2-139-2-159.

  10. Goh V, Engledow A, Rodríguez-Justo M, et al. The flow-metabolic phenotype of primary colorectal cancer: assessment by integrated 18F-FDG PET/perfusion CT with histopathologic correlation. J Nucl Med. 2012;53(5):687-92.

  11. Bucai CA. Marcadores tumorales de cáncer de colon. Rev Asoc Coloproct del Sur. 2007;2(2):90-106.

  12. Téllez AF, García OS. El antígeno carcinoembrionario: a propósito de un viejo conocido. Rev Invest Clin. 2005;57(6):814-9.

  13. López J, Molt F, Hornig A, Mariángel P, Avendaño R. Antígeno carcinoembrionario preoperatorio y riesgo de metástasis en el cáncer colorrectal. Cuad Cir. 2005;19:22-6.

  14. Actas de reuniones clínicas. PET en cáncer colorrectal. Medwave. 2008;8(9):e1717 doi: 10.5867/medwave.2008.09.1717.

  15. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon Cancer. Version 3.2012. NCCN.org.

  16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.

  17. Nishino M, Jagannathan J, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologist want to know and what radiologists need to know. AJR. 2010;195(2):281-9.

  18. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-50S.

  19. Lee JH, Park SG, Jee KN, Park DG, Namgung H, Song IH. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level. Nucl Med Commun. 2010;31(6):576-82.




2020     |     www.medigraphic.com